title: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
abstract: Vitamin D is a steroid hormone best known for its activity in regulating calcium and bone metabolism. Epidemiological evidence suggests that vitamin D may play a role in inhibiting the development of colon and prostate cancer. Vitamin D receptors are expressed in many types of malignant cells; in vitro and in vivo vitamin D and vitamin D analogues are active in suppressing the development and inhibiting the growth of numerous human and animal tumors. The major toxicity of the active form of vitamin D, 1,25-dihydroxycholecalciferol (calcitriol), is the induction of hypercalcemia. There are no data indicating the maximum tolerated dose of calcitriol administered every other day (QOD) s.c. We hypothesized that this route and schedule would permit administration of higher doses of calcitriol, which might have anticancer activity. We conducted a Phase I trial of calcitriol given s.c. QOD in patients with advanced solid tumors. Thirty-six patients were entered at doses ranging from 2 to 10 microg QOD; dose-limiting toxicity (hypercalcemia) occurred in three of three patients entered at the 10-microg QOD dose. Hypercalciuria occurred at all dose levels examined. No other toxicity was seen. Assessment of serum calcitriol concentrations by a RIA revealed a decrease in concentration-time curves on day 7 compared to day 1 of therapy. A dose-dependent increase in peak serum level and estimated area under the concentration-time curve was seen. The maximum serum levels occurred at the 10-microg QOD dose: 288 +/- 74 and 321 +/- 36 pg/ml at days 1 and 7, respectively. The normal range of calcitriol serum concentration, determined using this assay, is 16-56 pg/ml. Serum calcitriol levels were maintained at near peak concentrations for at least 8 h following s.c. injection. This study indicates that substantial doses of calcitriol can be administered via this route with tolerable toxicity. Studies to explore approaches to ameliorate the hypercalcemia induced by calcitriol and to explore alternative schedules and interactions with other agents are warranted.
authors.affiliation: Department of Medicine, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pennsylvania 15123, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Smith
authors.forename: C S
authors.initials: CS
authors.lastname: Johnson
authors.forename: C C
authors.initials: CC
authors.lastname: Freeman
authors.forename: J
authors.initials: J
authors.lastname: Muindi
authors.forename: J W
authors.initials: JW
authors.lastname: Wilson
authors.forename: D L
authors.initials: DL
authors.lastname: Trump
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D002117:Calcitriol / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D002118:Calcium / Q000097:blood / Q000652:urine; D002272:Carcinoembryonic Antigen / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D011863:Radioimmunoassay
chemical_list: D002272:Carcinoembryonic Antigen; D010281:Parathyroid Hormone; D002117:Calcitriol; D002118:Calcium